



# 专家风采

## 高栋

本期“Prostate Cell Fate and Diseases”专刊客座主编  
细胞生物学博士，中国科学院分子细胞科学卓越创新中心  
研究员。获国家杰出青年基金、上海市优秀学术带头人、  
国家青年人才计划等项目支持。担任《中国细胞生物学  
学报》编委、*Cancer Letters*编委、*Journal of Cellular and  
Molecular Medicine*编委、*Life Medicine*编委等。



## 学术兼职

中国医药生物技术协会疾病模型专业委员会副主任委员、中国细胞生物学学会细胞  
工程与转基因生物专委会委员、中国抗癌协会肿瘤标志专委会委员等职务。

## 科研方向

长期从事干细胞和肿瘤细胞命运可塑性研究。近年来利用多学科交叉的方法研究成  
体干细胞谱系命运转变机制，系统阐明肿瘤进展和治疗抵抗条件下的肿瘤细胞命运  
可塑性调控机制等科学问题。已在*Cell*, *Cancer Cell*, *Nature Genetics*, *Cell Stem Cell*,  
*Cell Research*, *Journal of Clinical Investigation*, *Nature Communications*等期刊发表论文  
57篇。

## EXPERTS IN CHINA

**Dr. Dong Gao** is Principal Investigator of Shanghai Institute of Biochemistry and Cell  
Biology, Chinese Academy of Sciences. Dr. Gao serves as deputy director of the Society for  
Disease Modelling (China Medicinal Biotech Association), the Committee at the Society for  
Cell Engineering & Transgenic Biology (Chinese Society for Cell Biology) and the Tumor  
Marker Committee of Chinese Anti-Cancer Association. Dr. Gao serves as Guest Editor for  
this special issue of “Prostate Cell Fate and Diseases” in *Asian Journal of Andrology*. He is  
also the editor board member of *Chinese Journal of Cell Biology*, *Cancer Letters*, *Journal of  
Cellular and Molecular Medicine* and *Life Medicine*.

The research of his group focus on: 1) defining the role of novel progenitor cells and their  
lineage plasticity in tissue homeostasis and cancer initiation, 2) defining the pioneering  
forces shaping the lineage plasticity of prostate cancer progression and therapeutic resis-  
tance, 3) developing pharmacological strategies to overcome current therapy resistance  
using clinical grade inhibitors, and 4) generating patients-derived organoid models to reca-  
pitulate the lineage plasticity seen in patients and identify the molecular mechanisms of  
cancer cell lineage plasticity. To date, Dr. Gao has published 57 scientific papers on *Cell*,  
*Cancer Cell*, *Nature Genetics*, *Cell Stem Cell*, *Cell Research*, *Journal of Clinical Investigation*,  
*Nature Communications*, etc.

(March 2023)